Alphatec Holdings, Inc. $ATEC Stake Cut by Motley Fool Wealth Management LLC

Motley Fool Wealth Management LLC cut its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 13.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 837,084 shares of the medical technology company’s stock after selling 130,852 shares during the period. Alphatec accounts for 1.4% of Motley Fool Wealth Management LLC’s investment portfolio, making the stock its 19th biggest position. Motley Fool Wealth Management LLC’s holdings in Alphatec were worth $17,612,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Franklin Resources Inc. lifted its stake in Alphatec by 2.0% during the fourth quarter. Franklin Resources Inc. now owns 64,774 shares of the medical technology company’s stock worth $1,363,000 after purchasing an additional 1,299 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its stake in Alphatec by 233.4% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 45,445 shares of the medical technology company’s stock valued at $956,000 after buying an additional 31,813 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Alphatec by 29.9% in the fourth quarter. JPMorgan Chase & Co. now owns 579,066 shares of the medical technology company’s stock valued at $12,184,000 after buying an additional 133,365 shares during the last quarter. AXQ Capital LP bought a new stake in Alphatec in the fourth quarter valued at $441,000. Finally, BNP Paribas Financial Markets lifted its stake in Alphatec by 11.3% in the fourth quarter. BNP Paribas Financial Markets now owns 708,548 shares of the medical technology company’s stock valued at $14,908,000 after buying an additional 71,933 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Barclays cut their target price on Alphatec from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Needham & Company LLC cut their target price on Alphatec from $25.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Stifel Nicolaus cut their target price on Alphatec from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 9th. Wells Fargo & Company cut their target price on Alphatec from $28.00 to $14.00 and set an “overweight” rating on the stock in a research note on Thursday, May 7th. Finally, Canaccord Genuity Group lowered their target price on Alphatec from $25.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.58.

Insider Activity at Alphatec

In related news, COO Scott Lish sold 260,535 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $12.30, for a total value of $3,204,580.50. Following the completion of the sale, the chief operating officer owned 815,704 shares of the company’s stock, valued at approximately $10,033,159.20. The trade was a 24.21% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 13.48% of the company’s stock.

Alphatec Trading Up 4.4%

NASDAQ:ATEC opened at $8.26 on Wednesday. The company has a debt-to-equity ratio of 40.35, a current ratio of 1.90 and a quick ratio of 1.12. Alphatec Holdings, Inc. has a fifty-two week low of $6.82 and a fifty-two week high of $23.29. The stock’s 50-day moving average is $9.29 and its two-hundred day moving average is $14.15. The stock has a market cap of $1.27 billion, a PE ratio of -10.07 and a beta of 0.88.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, May 5th. The medical technology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.21). Alphatec had a negative net margin of 15.93% and a negative return on equity of 1,183.84%. The business had revenue of $192.11 million for the quarter, compared to analysts’ expectations of $197.51 million. During the same period last year, the firm earned ($0.35) EPS. The company’s revenue was up 13.6% compared to the same quarter last year. As a group, equities research analysts forecast that Alphatec Holdings, Inc. will post -0.44 earnings per share for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.